Stanton Marshall S. 的 Form 4/A 修正申報
修正Artivion, Inc.（AORT），2024/3/14 申報
- 申報編號
- 0000784199-24-000154
- 申報時間
- 2024/3/14
- 交易日
- 2024/2/23-2/26
- 申報延遲
- 20 天
- 10b5-1 計畫
- 沒有勾選
- 原始申報日
- 2024/2/28
這份申報列了 4 筆非衍生性交易。公開市場賣出合計 $6.10 萬。交易後 20 天申報。
這份修正申報取代了 0000784199-24-000059（2024/2/28 申報）。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| Stanton Marshall S.CIK 0001849615 | 高階主管（SVP, Clinical & MD Affair） |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
| 交易日 | 證券 | 交易 | 股數 | 價格 | 金額 | 交易後持股 | 持有方式 | 旗標 |
|---|---|---|---|---|---|---|---|---|
| 2024/2/23 | Common Stock | A公司授予取得 | +5,386 | $0.00 | $0 | 74,089 | 直接 | |
| 2024/2/26 | Common Stock | S賣出處分 | −1,576 | $20.27 | −$31,945.52 | 72,513 | 直接 | |
| 2024/2/23 | Common Stock | A公司授予取得 | +10,644 | $0.00 | $0 | 83,157 | 直接 | |
| 2024/2/26 | Common Stock | S賣出處分 | −1,431 | $20.27 | −$29,006.37 | 81,726 | 直接 |
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
Represents performance stock units granted on Feb. 22, 2023. One hundred percent (100%) were issued on Feb. 23, 2024.
- F2
These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. This amendment is being filed to address an administrative error in reporting the number of shares sold in the sell to cover transaction on February 26, 2024. The original Form 4 reported that 1,600 shares were sold, when in fact, 1,576 shares were sold.
- F3
As a result of the administrative error in reporting the number of shares sold in the sell to cover transactions on February 26, 2024, the number of shares reported as beneficially owned in this amendment reflects an increase in the number of shares reported as beneficially owned in the original Form 4.
- F4
Represents performance stock units granted on Feb. 22, 2023. Fifty percent (50%) were issued on Feb. 23, 2024. The remaining shares earned in connection with the Feb. 2023 grant will be eligible to vest and be issued as follows: 25% on 02/22/2025; and 25% on 02/22/2026, assuming employment on the relevant vesting date.
- F5
These shares were sold upon the vesting of performance stock units to pay tax withholding obligations. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction. This amendment is being filed to address an administrative error in reporting the number of shares sold in the sell to cover transaction on February 26, 2024. The original Form 4 reported that 1,448 shares were sold, when in fact, 1,431 shares were sold.